Comparison of the immunomodulatory effect of single MSC batches versus pooled MSC products

Hejretová, L; Čedíková, Miroslava; Dolejšová, M.; Vlas, Tomas; Зак, Павел; Lysák, Daniel; Holubová, Monika

doi:10.1007/s10561-019-09805-3

Cited by 6 publications

(3 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…MSCs have been extensively used as cell-based therapies predominantly for their anti-inflammatory and immunomodulatory non-stem cell properties (26). They have also potential for tissue engineering purposes for regenerating new tissues or promoting the activity of endogenous stem cells (27).…”

Section: Discussionmentioning

confidence: 99%

The cytotoxicity of advanced glycation end products was attenuated by UCMSCs in human vaginal wall fibroblasts by inhibition of an inflammatory response and activation of PI3K/AKT/PTEN

Sima

Wang

et al. 2020

BST

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

The cytotoxicity of advanced glycation end products was attenuated by UCMSCs in human vaginal wall fibroblasts by inhibition of an inflammatory response and activation of PI3K/AKT/PTEN

Sima

Wang

et al. 2020

BST

View full text Add to dashboard Cite

“…Whilst the functional role that MSC play is still not fully elicited their ability to modulate the immune system has been well described (40,41). Variation in human MSC function has been variably ascribed to different batches, donor sources and donor age, however evidence is mixed and there is as yet no standardized source or donor demographic definition to inform cell therapy in clinical trials (42)(43)(44)(45)(46)(47). It has also been demonstrated that adipose MSC derived from obese donors have reduced proliferative and differentiation ability (48).…”

Section: Mesenchymal Stromal Cellsmentioning

confidence: 99%

Mesenchymal Stromal Cells, a New Player in Reducing Complications From Liver Transplantation?

Owen

Newsome

2020

Front. Immunol.

View full text Add to dashboard Cite

In response to the global burden of liver disease there has been a commensurate increase in the demand for liver transplantation. However, due to a paucity of donor organs many centers have moved toward the routine use of marginal allografts, which can be associated with a greater risk of complications and poorer clinical outcomes. Mesenchymal stromal cells (MSC) are a multi-potent progenitor cell population that have been utilized to modulate aberrant immune responses in acute and chronic inflammatory conditions. MSC exert an immunomodulatory effect on innate and adaptive immune systems through the release of both paracrine soluble factors and extracellular vesicles. Through these routes MSC can switch the regulatory function of the immune system through effects on macrophages and T regulatory cells enabling a switch of phenotype from injury to restoration. A key benefit seems to be their ability to tailor their response to the inflammatory environment without compromising the host ability to fight infection. With over 200 clinical trials registered to examine MSC therapy in liver disease and an increasing number of trials of MSC therapy in solid organ transplant recipients, there is increasing consideration for their use in liver transplantation. In this review we critically appraise the potential role of MSC therapy in the context of liver transplantation, including their ability to modulate reperfusion injury, their role in the reduction of medium term complications in the biliary tree and their potential to enhance tolerance in transplanted organs.

show abstract

“…В то же время, в исследовании, которое было проведено в 2019 году Hejretová, L. и коллегами, было выполнено сравнение 5 монокультур МСК костного мозга и пулированной культуры МСК, полученной путем смешивания этих культур. Показано отсутствие разницы между моно-и пулированной культурой в отношении влияния на активацию Т-лимфоцитов, также не выявлено различий в их морфологии, иммунофенотипе, метаболизме и пролиферации [20].…”

Section: экспериментальное и доклиническое изучение терапевтического потенциала пулмскunclassified

Acquisition and medical application of pooled mesenchimal stem cells

Rynda¹,

Antonevich²,

Гончаров³

2020

Immunopathol Allergol Infectol

View full text Add to dashboard Cite

Мезенхимальные стволовые клетки (МСК) прочно зарекомендовали себя в качестве клеточного продукта для лечения обширного спектра заболеваний. Однако существуют ограничения использования аутологичных МСК, связанные с невозможностью накопления достаточного количества клеточной биомассы от одного донора, а также абберантными свойствами клеток, полученных от больных людей. Также проблемой является обширная индивидуальная гетерогенность свойств и характеристик МСК разных доноров. В последние годы появляется все больше данных о том, что пулированные культуры аллогенных МСК (пулМСК) обладают более выраженными и стабильными иммуномодулирующими свойствами, в сравнении с МСК, полученными от одного донора. Благодаря их доказанному иммуномодулирующему и регенеративному потенциалу, а также безопасности и хорошей переносимости, применение пулМСК в медицине выглядит перспективны. Целью данной статьи было изучение существующих на данных момент литературных данных, в которых описаны морфологические, функциональные и иммунофенотипические свойства пулированных культур МСК, а также опыт их применения в доклинических исследованиях. Ключевые слова Стволовые клетки, пулированные культуры, пулированные мезенхимальные стволовые клетки, клеточная терапия SummaryMesenchymal stem cells (MSCs) have long been considered as a cell product for treatment of a wide range of pathology. However, there are limitations to use of autologous MSCs associated with the impossibility of accumulating a sufficient amount of cellular biomass from a single donor, as well as aberrant characteristics of cells obtained from patients. Another problem is the extensive individual heterogeneity of properties and characteristics of MSCs of different donors. In recent years, more and more evidence has appeared that pooled cultures of allogeneic MSCs (poolMSC) have more pronounced and stable immunomodulating properties, compared with MSCs obtained from a single donor. Due to their proven immunomodulatory and regenerative potential, as well as safety and good tolerance, the use of poolMSC in medicine looks promising. The purpose of this article was to study the currently available data that describe the morphological, functional and immunophenotypic properties of the pooled cultures of MSCs, as well as the experience of their application in preclinical studies.

show abstract

Comparison of the immunomodulatory effect of single MSC batches versus pooled MSC products

Cited by 6 publications

References 39 publications

The cytotoxicity of advanced glycation end products was attenuated by UCMSCs in human vaginal wall fibroblasts by inhibition of an inflammatory response and activation of PI3K/AKT/PTEN

The cytotoxicity of advanced glycation end products was attenuated by UCMSCs in human vaginal wall fibroblasts by inhibition of an inflammatory response and activation of PI3K/AKT/PTEN

Mesenchymal Stromal Cells, a New Player in Reducing Complications From Liver Transplantation?

Acquisition and medical application of pooled mesenchimal stem cells

Contact Info

Product

Resources

About